Cargando…

Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs

BACKGROUND: Women with abnormal uterine bleeding (AUB) may be treated surgically with hysterectomy or global endometrial ablation (GEA), an outpatient procedure. We compared the costs and clinical outcomes of these surgical procedures for AUB among women in Medicaid programs. METHODS: The Truven Hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonafede, Machaon M, Miller, Jeffrey D, Laughlin-Tommaso, Shannon K, Lukes, Andrea S, Meyer, Nicole M, Lenhart, Gregory M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199837/
https://www.ncbi.nlm.nih.gov/pubmed/25336979
http://dx.doi.org/10.2147/CEOR.S67888
_version_ 1782339983595536384
author Bonafede, Machaon M
Miller, Jeffrey D
Laughlin-Tommaso, Shannon K
Lukes, Andrea S
Meyer, Nicole M
Lenhart, Gregory M
author_facet Bonafede, Machaon M
Miller, Jeffrey D
Laughlin-Tommaso, Shannon K
Lukes, Andrea S
Meyer, Nicole M
Lenhart, Gregory M
author_sort Bonafede, Machaon M
collection PubMed
description BACKGROUND: Women with abnormal uterine bleeding (AUB) may be treated surgically with hysterectomy or global endometrial ablation (GEA), an outpatient procedure. We compared the costs and clinical outcomes of these surgical procedures for AUB among women in Medicaid programs. METHODS: The Truven Health MarketScan(®) Medicaid Multi-State Database was used to identify Medicaid women aged 30–55 years with AUB who newly initiated GEA or hysterectomy (index event) during 2006–2010. Patients were required to have 12 months of continuous enrollment pre-index and post-index. Baseline characteristics were assessed in the pre-index period; health care utilization and costs (2011 USD), treatment complications, and reinterventions were assessed in the post-index period. RESULTS: Of 1,880 women who met the study criteria (mean age 40.7 years), 53.4% were Caucasian, 33.1% were African-American, and 2.3% were Hispanic; many (42.8%) received their Medicaid eligibility due to disability. Similar proportions received GEA (50.9%) or hysterectomy (49.1%). At baseline, both groups also had similar Deyo-Charlson Comorbidity scores (0.65), and use of antibiotics (69.4%), nonsteroidal anti-inflammatory drugs (56.3%), and oral contraceptives (5.3%). More hysterectomy patients than GEA patients had a treatment-related complication (52% versus 36%, respectively, P<0.001). Initial treatment costs were higher for hysterectomy ($11,270) than for GEA ($3,958, P<0.001); monthly gynecology-related costs in the remainder of the year were not significantly different for hysterectomy ($63) and GEA ($16, P=0.11). CONCLUSION: Hysterectomy was nearly three times more costly than GEA for initial treatment of AUB, and associated with more treatment-related complications. These results may be informative in the context of new federal mandates for Medicaid expansion, which are likely to focus on cost savings through use of outpatient treatments such as GEA.
format Online
Article
Text
id pubmed-4199837
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41998372014-10-21 Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs Bonafede, Machaon M Miller, Jeffrey D Laughlin-Tommaso, Shannon K Lukes, Andrea S Meyer, Nicole M Lenhart, Gregory M Clinicoecon Outcomes Res Original Research BACKGROUND: Women with abnormal uterine bleeding (AUB) may be treated surgically with hysterectomy or global endometrial ablation (GEA), an outpatient procedure. We compared the costs and clinical outcomes of these surgical procedures for AUB among women in Medicaid programs. METHODS: The Truven Health MarketScan(®) Medicaid Multi-State Database was used to identify Medicaid women aged 30–55 years with AUB who newly initiated GEA or hysterectomy (index event) during 2006–2010. Patients were required to have 12 months of continuous enrollment pre-index and post-index. Baseline characteristics were assessed in the pre-index period; health care utilization and costs (2011 USD), treatment complications, and reinterventions were assessed in the post-index period. RESULTS: Of 1,880 women who met the study criteria (mean age 40.7 years), 53.4% were Caucasian, 33.1% were African-American, and 2.3% were Hispanic; many (42.8%) received their Medicaid eligibility due to disability. Similar proportions received GEA (50.9%) or hysterectomy (49.1%). At baseline, both groups also had similar Deyo-Charlson Comorbidity scores (0.65), and use of antibiotics (69.4%), nonsteroidal anti-inflammatory drugs (56.3%), and oral contraceptives (5.3%). More hysterectomy patients than GEA patients had a treatment-related complication (52% versus 36%, respectively, P<0.001). Initial treatment costs were higher for hysterectomy ($11,270) than for GEA ($3,958, P<0.001); monthly gynecology-related costs in the remainder of the year were not significantly different for hysterectomy ($63) and GEA ($16, P=0.11). CONCLUSION: Hysterectomy was nearly three times more costly than GEA for initial treatment of AUB, and associated with more treatment-related complications. These results may be informative in the context of new federal mandates for Medicaid expansion, which are likely to focus on cost savings through use of outpatient treatments such as GEA. Dove Medical Press 2014-10-08 /pmc/articles/PMC4199837/ /pubmed/25336979 http://dx.doi.org/10.2147/CEOR.S67888 Text en © 2014 Bonafede et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Bonafede, Machaon M
Miller, Jeffrey D
Laughlin-Tommaso, Shannon K
Lukes, Andrea S
Meyer, Nicole M
Lenhart, Gregory M
Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
title Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
title_full Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
title_fullStr Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
title_full_unstemmed Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
title_short Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
title_sort retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in us medicaid programs
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199837/
https://www.ncbi.nlm.nih.gov/pubmed/25336979
http://dx.doi.org/10.2147/CEOR.S67888
work_keys_str_mv AT bonafedemachaonm retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms
AT millerjeffreyd retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms
AT laughlintommasoshannonk retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms
AT lukesandreas retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms
AT meyernicolem retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms
AT lenhartgregorym retrospectivedatabaseanalysisofclinicaloutcomesandcostsfortreatmentofabnormaluterinebleedingamongwomenenrolledinusmedicaidprograms